Oncology Archives - Page 10 of 22

Relapsed multiple myeloma in the UK prior to the introduction of novel agents – a response to Koleva et al. (2010)

Authors: J Quinn, F Percival, M Auger, S Basu, P Chu, M Aldouri, A Lambourne, S Gaugris, K Yong Published: European Journal of Cancer Care, 2011 View publication No abstract available

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

Authors: F Djebbari, F A Sharpley, S McLain-Smith, G Vallance, T A Eyre, J Kothari, S Moore, K Ramasamy Published: PLOS One, 2020 View publication Abstract Treatment of transplant-ineligible (TNE) newly diagnosed...

Patient preferences for benefits, risks, and administration route of hypomethylating agents in myelodysplastic syndromes

Authors: A M Zeidan. J Tsai, M Karimi, J Schmier, S Jayade, E Zormpas, A Hassan, D Ruiters, C Anthony, K Hill, T Wert, M Botteman Published: Clinical Lymphoma Myeloma & Leukemi,...

Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom

Authors: M Mohty, W Knauf, D Romanus, S Corman, K Verleger, Y Kwon, D Cherepanov, M J Cambron-Mellott, H G Vikis, F Gonzalez, F Gavini, K Ramasamy Published: European Journal of Hematology,...

Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer

Authors: A Aly, R Shah, K Hill, M F Botteman Published: Future Oncology, 2019 View publication Aim This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative...

Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study

Authors: A Aly, P Singh, B Korytowsky, Y Ling, H P Kale, H B Dastani, M F Botteman, A D Norden Published: Neuro-oncology Practice, 2020 View publication Background Glioblastoma (GBM) is associated...

The real-world lifetime economic burden of urothelial carcinoma by stage at diagnosis

Authors: A Aly, C Johnson, Y Doleh, V Chirikov, M Botteman, R Shenolikar, A Hussain Published: Journal of clinical pathways : the foundation of value-based care, 2020 View publication Background Urothelial carcinoma...

The cost of anal cancer in England: retrospective hospital data analysis and Markov model

Authors: S T Keeping, M J Tempest, S J Stephens, S M Carroll, K P Nugent & S T O'Dwyer Published: BMC Public Health, 2014 View publication Background Anal cancer requires a...

Payers’ views on the heterogeneity of treatment effect in oncology

Authors: A Abdalla, D Yoder, F Pradel, D C Mullins Published: The American Journal of Pharmacy Benefits, 2017 View publication Objectives The heterogeneity of treatment effect (HTE) refers to the nonrandom variability...

News